NCT01743157View on ClinicalTrials.gov

Biochemotherapy and Bevacizumab Followed by Consolidation Therapy With Ipilimumab for Metastatic Melanoma

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

December 31, 2010

Primary Completion Date

May 31, 2013

Study Completion Date

May 31, 2013

Conditions
Metastatic Melanoma
Interventions
DRUG

Biochemo + bevacizumab then ipilimumab

Bevacizumab 7.5mg/kg week 1,repeat weeks 4,7,10 (cycles 2, 3, \& 4)

Trial Locations (1)

94115

San Francisco Oncology Associates, San Francisco

Sponsors
All Listed Sponsors
lead

California Pacific Medical Center Research Institute

OTHER